IL315510A - MHC IB-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease - Google Patents

MHC IB-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease

Info

Publication number
IL315510A
IL315510A IL315510A IL31551024A IL315510A IL 315510 A IL315510 A IL 315510A IL 315510 A IL315510 A IL 315510A IL 31551024 A IL31551024 A IL 31551024A IL 315510 A IL315510 A IL 315510A
Authority
IL
Israel
Prior art keywords
mhc
multiple sclerosis
novel treatment
specific immunosuppression
mog antibody
Prior art date
Application number
IL315510A
Other languages
English (en)
Hebrew (he)
Original Assignee
Julius Maximilians Universit?T W?Rzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universit?T W?Rzburg filed Critical Julius Maximilians Universit?T W?Rzburg
Publication of IL315510A publication Critical patent/IL315510A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL315510A 2022-03-24 2023-03-24 MHC IB-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease IL315510A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164122 2022-03-24
PCT/EP2023/057679 WO2023180546A1 (en) 2022-03-24 2023-03-24 Mho ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease

Publications (1)

Publication Number Publication Date
IL315510A true IL315510A (en) 2024-11-01

Family

ID=81389016

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315510A IL315510A (en) 2022-03-24 2023-03-24 MHC IB-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and MOG antibody disease

Country Status (12)

Country Link
US (1) US20250222083A1 (cg-RX-API-DMAC7.html)
EP (1) EP4499676A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025513720A (cg-RX-API-DMAC7.html)
KR (1) KR20240162578A (cg-RX-API-DMAC7.html)
CN (1) CN118922435A (cg-RX-API-DMAC7.html)
AU (1) AU2023240382A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255287A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002837A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013220A2 (cg-RX-API-DMAC7.html)
IL (1) IL315510A (cg-RX-API-DMAC7.html)
MX (1) MX2024011667A (cg-RX-API-DMAC7.html)
WO (1) WO2023180546A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519540A (zh) * 2023-09-22 2025-05-16 德國符茲堡大學 MHC Ib媒介之髓磷脂特異性免疫抑制作為用於多發性硬化症及MOG抗體疾病之新穎治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
US11464840B2 (en) * 2018-02-26 2022-10-11 Swey-Shen Chen Universal non-classical MHC I vaccines: HLA-E-restricted antigenic peptides as universal vaccines to treat allergy, inflammation, autoimmune and infectious diseases, and cancers

Also Published As

Publication number Publication date
WO2023180546A1 (en) 2023-09-28
CA3255287A1 (en) 2023-09-28
US20250222083A1 (en) 2025-07-10
AU2023240382A1 (en) 2024-11-14
WO2023180546A8 (en) 2024-10-17
CL2024002837A1 (es) 2025-02-21
JP2025513720A (ja) 2025-04-30
EP4499676A1 (en) 2025-02-05
CO2024013220A2 (es) 2024-10-31
MX2024011667A (es) 2024-09-27
KR20240162578A (ko) 2024-11-15
CN118922435A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
EP3954395A4 (en) Pharmaceutical composition for muscle disease treatment
RU2014136332A (ru) Композиции и способы применения ингибиторов csf1r
JP2020500181A5 (cg-RX-API-DMAC7.html)
ECSP10010251A (es) ANTICUERPOS MONOCLONALES QUE SE UNEN AL hGM-CSF Y COMPOSICIONES MÉDICAS QUE LOS COMPRENDEN
MX2021010568A (es) Leucina, acetilleucina y analogos relacionados para el tratamiento de enfermedades.
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
JP2014502955A5 (cg-RX-API-DMAC7.html)
RU2430111C3 (ru) Молекулы антител с улучшенными свойствами
WO2008149354A3 (en) Agents for the treatment of inflammatory diseases and methods of using same
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
EP4298093A4 (en) ANALOGUES FOR THE TREATMENT OF DISEASE
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
CA3305597A1 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
PH12022551500A1 (en) Bispecific anti-ccl2 antibodies
AU2022296903A1 (en) Treatment for autoimmune diseases
GB202307118D0 (en) Therapeutic composition
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
GB2612154B (en) Medication auto-injectors
GB202311497D0 (en) Therapeutic antibodies
GB202402048D0 (en) Therapeutic antibodies
GB202401988D0 (en) Therapeutic antibodies
IL314314A (en) Therapeutic antibodies
GB202300904D0 (en) Therapeutic antibodies
GB202217993D0 (en) Therapeutic antibodies